Itamar Medical Ltd. (NASDAQ:ITMR) is reporting third quarter financial results on Tuesday 17th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ITMR is expected to report 3Q20 loss of $ 0.15 per share from revenue of $ 9.94 million.
For the full year, analysts anticipate top line of $ 38.65 million, while looking forward to loss of $ 0.59 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 10.70 million ~ $ 11.00 million
Full Year 2020 topline are forecasted in a range of$ 39.50 million ~ $ 40.50 million
Click Here For More Historical Outlooks Of Itamar Medical Ltd.
Previous Quarter Performance
Itamar Medical Ltd. came out with loss for the second quarter of $ 0.17 per share, from the revenue of $ 8.88 million. The quarterly revenues elevated 20.82 percent compared with the same quarter last year. Wall street analysts are predicting, ITMR to report 2Q20 loss of $ 0.19 per share from revenue of $ 7.81 million. The bottom line results beat street analysts by $ 0.02 or 10.53 percent, at the same time, top line results outshined analysts by $ 1.07 million or 13.70 percent.
Stock Performance
Shares of Itamar Medical Ltd. traded up $ 0.06 or 0.32 percent on Monday, reaching $ 19.07 with volume of 112.70 thousand shares. Itamar Medical Ltd. has traded high as $ 19.47 and has cracked $ 18.60 on the downward trend
According to the previous trading day, closing price of $ 19.07, representing a 143.09 % increase from the 52 week low of $ 7.82 and a 34.45 % decrease over the 52 week high of $ 29.00.
The company has a market capital of $ 259.82 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Itamar Medical Ltd. will be hosting a conference call at 8:00 AM eastern time on 17th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 833-519-1272 or 914-800-3844 (International), when prompted, enter passcode 7976547 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.itamar-medical.com
Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market in the United States and Canada, Europe, Israel, Japan, the Asia Pacific, and internationally. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patients peripheral arterial pulse volumes and various parameters of arterial activities.
